Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition

Executive Summary

GlaxoSmithKline Flonase Sensimist Allergy Relief could help fend off private label competition in the intranasal corticosteroid category, the firm says. Despite a 19% drop in sales of the original Flonase OTC in the fourth quarter, US consumer health care sales grew 5% to $2.2bn on a reported basis in 2016.


Related Content

GSK Management Shake Up Ahead Of New CEO Sees Hussain Out, AZ's Miels In
GSK's Flonase Sensimist (Veramyst) Switches Name On Way To OTC
Fluticasone Spray Competition Grows With Perrigo Launch Of West-Ward Product
Glaxo In Charge, And The World Is GSK/Novartis Consumer Product JV’s Oyster


Related Companies